Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Savara (SVRA)
NASDAQ:SVRA
Savara (SVRA) Stock Price & Analysis
1,059 Followers
SVRA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.93 - $5.70
Previous Close$4.33
Volume747.30K
Average Volume (3M)1.73M
Market Cap
$707.07M
Enterprise Value$590.39M
Total Cash (Recent Filing)$143.10M
Total Debt (Recent Filing)$26.42M
Price to Earnings (P/E)―
Beta0.84
Next Earnings
Aug 08, 2024EPS Estimate
-$0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.38
Shares Outstanding138,188,891
10 Day Avg. Volume1,087,302
30 Day Avg. Volume1,727,315
Standard Deviation0.40
R-Squared0.00825
Alpha0.03
Financial Highlights & Ratios
Price to Book (P/B)4.14
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-8.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-11.48
Forecast
1Y Price Target
$10.43Price Target Upside140.88% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Savara News
PremiumCompany Announcements
Savara’s IMPALA-2 Trial Success and FDA Submission PlanBulls Say, Bears Say
Bulls Say
Clinical Trial ResultsThe pivotal Phase III study of Molgramostim was positive on the DLCO primary and key functional secondaries in aPAP, a rare lung disease with no approved therapies.
Market PotentialSuccess in IMPALA-2 will support molgramostim replacing WLL as standard of care for aPAP — an underappreciated commercial opportunity.
Patient OutcomesMolgra patients are functionally improving over time, with robust efficacy and a clean safety profile.
Bears Say
Healthcare CostsPatients with untreated pulmonary alveolar proteinosis face higher comorbidities and increased healthcare utilization costs compared to those with confirmed diagnoses.
Operating Expenses1Q24 operating expenses reached $22 million, surpassing consensus estimates and contributing to a net loss of $20 million for the quarter.
Product CostThe high cost of Leukine and challenges in securing insurance coverage present significant barriers to patients starting medical therapy.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
SVRA FAQ
What was Savara’s price range in the past 12 months?
Savara lowest stock price was $2.93 and its highest was $5.70 in the past 12 months.
What is Savara’s market cap?
Currently, no data Available
When is Savara’s upcoming earnings report date?
Savara’s upcoming earnings report date is Aug 08, 2024 which is in 34 days.
How were Savara’s earnings last quarter?
Savara released its earnings results on May 09, 2024. The company reported -$0.11 earnings per share for the quarter, missing the consensus estimate of -$0.099 by -$0.011.
Is Savara overvalued?
According to Wall Street analysts Savara’s price is currently Undervalued.
Does Savara pay dividends?
Savara does not currently pay dividends.
What is Savara’s EPS estimate?
Savara’s EPS estimate is -$0.1.
How many shares outstanding does Savara have?
Savara has 164,435,610 shares outstanding.
What happened to Savara’s price movement after its last earnings report?
Savara reported an EPS of -$0.11 in its last earnings report, missing expectations of -$0.099. Following the earnings report the stock price went down -8.087%.
Which hedge fund is a major shareholder of Savara?
Among the largest hedge funds holding Savara’s share is Farallon Capital Management, L.L.C.. It holds Savara’s shares valued at 12M.
---
Savara Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$10.43 (140.88% Upside)
$10.43 (140.88% Upside)
Blogger Sentiment
Bullish
SVRA Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 3.9M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.2%
Last 30 Days ▲ 8.0%
Last 30 Days ▲ 8.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
36.59%
12-Months-Change
Fundamentals
Return on Equity
-58.59%
Trailing 12-Months
Asset Growth
22.37%
Trailing 12-Months
Company Description
Savara
Savara, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. Its products include AeroVanc, Molgradex, GM-CSF, and Aironite. The company was founded on April 27, 2017 and is headquartered in Austin, TX.
---
SVRA Stock 12 Month Forecast
Average Price Target
$10.43
▲(140.88% Upside)
Technical Analysis
Best Analysts Covering SVRA
1 Year
1 Year Success Rate
7/9 ratings generated profit
1 Year Average Return
+68.87%
reiterated a buy rating 8 days ago
Copying Andrew Fein's trades and holding each position for 1 Year would result in 77.78% of your transactions generating a profit, with an average return of +68.87% per trade.
---